Merus NV
MRUS66.192USD
+0.632+0.96%
交易中 （美东）报价延迟15分钟
4.58B总市值
亏损市盈率 TTM
关于 Merus NV 公司
Merus NV 是一家总部位于荷兰的生物技术公司，专注于为癌症患者开发差异化疗法。Merus 的产品线基于 Multiclonics 格式。其产品旨在与多个靶标结合，并具有抗癌作用，可对抗驱动癌症的复杂机制。该公司的产品利用技术平台与癌症抗原结合，并利用免疫系统的力量杀死肿瘤细胞。其中一种药物 zenocutuzumab (Zeno) 是一种 Biclonics 抗体，专注于帮助肺癌、胰腺癌和其他类型实体瘤患者。该公司在荷兰和美国开展业务。
公司简介
公司代码MRUS
公司名称Merus NV
上市日期May 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
员工数量260
证券类型Ordinary Share
年结日May 19
公司地址Uppsalalaan 17, 3rd & 4th floor
城市UTRECHT
上市交易所NASDAQ Global Market Consolidated
国家Netherlands
邮编3584 CT
电话31850162500
网址https://merus.nl/
公司代码MRUS
上市日期May 19, 2016
CEODr. Sven Ante (Bill) Lundberg, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
7.55%
Wellington Management Company, LLP
6.34%
Commodore Capital LP
6.01%
RTW Investments L.P.
5.60%
Paradigm BioCapital Advisors LP
4.77%
Other
69.72%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
35.42%
Hedge Fund
34.84%
Investment Advisor
23.80%
Corporation
1.96%
Research Firm
1.56%
Venture Capital
1.48%
Private Equity
1.43%
Individual Investor
0.38%
Pension Fund
0.36%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
409
75.54M
101.47%
-10.37M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
2023Q1
250
43.88M
95.34%
-4.11M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
5.62M
7.55%
-39.01K
-0.69%
Mar 31, 2025
Wellington Management Company, LLP
4.72M
6.34%
+1.22M
+34.90%
Mar 31, 2025
Commodore Capital LP
4.47M
6.01%
+598.66K
+15.45%
Mar 31, 2025
RTW Investments L.P.
4.17M
5.6%
--
--
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.55M
4.77%
+184.36K
+5.47%
Apr 03, 2025
Deerfield Management Company, L.P.
3.17M
4.26%
+201.14K
+6.77%
Mar 31, 2025
Avoro Capital Advisors LLC
3.00M
4.03%
+875.00K
+41.18%
Mar 31, 2025
Samlyn Capital, LLC
2.38M
3.2%
-288.75K
-10.82%
Mar 31, 2025
Franklin Advisers, Inc.
1.94M
2.6%
+3.50K
+0.18%
Mar 31, 2025
Holocene Advisors, LP
1.87M
2.52%
-6.39K
-0.34%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Tema Oncology ETF
3.92%
ALPS Medical Breakthroughs ETF
2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.51%
Harbor Health Care ETF
1.1%
First Trust IPOX Europe Equity Opportunities ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
JPMorgan Healthcare Leaders ETF
0.62%
ProShares Ultra Nasdaq Biotechnology
0.41%
Invesco Nasdaq Biotechnology ETF
0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
0.39%
查看更多
Tema Oncology ETF
占比3.92%
ALPS Medical Breakthroughs ETF
占比2.65%
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.51%
Harbor Health Care ETF
占比1.1%
First Trust IPOX Europe Equity Opportunities ETF
占比1.04%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
JPMorgan Healthcare Leaders ETF
占比0.62%
ProShares Ultra Nasdaq Biotechnology
占比0.41%
Invesco Nasdaq Biotechnology ETF
占比0.41%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.39%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
